ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00320385

Public ClinicalTrials.gov record NCT00320385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens

Study identification

NCT ID
NCT00320385
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
296 participants

Conditions and interventions

Interventions

  • Lapatinib Drug
  • Trastuzumab Biological

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2005
Primary completion
May 31, 2007
Completion
Sep 30, 2010
Last update posted
Feb 25, 2016

2005 – 2010

United States locations

U.S. sites
87
U.S. states
25
U.S. cities
82
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85012
GSK Investigational Site Sedona Arizona 86336
GSK Investigational Site Highland California 92346
GSK Investigational Site Sacramento California 95819
GSK Investigational Site San Diego California 92120
GSK Investigational Site San Francisco California 94115-1710
GSK Investigational Site Santa Rosa California 95403-1757
GSK Investigational Site Vallejo California 94589
GSK Investigational Site Newark Delaware 19713
GSK Investigational Site Boca Raton Florida 33428
GSK Investigational Site Fort Myers Florida 33916
GSK Investigational Site Gainesville Florida 32605
GSK Investigational Site Hollywood Florida 33021
GSK Investigational Site Jacksonville Florida 32256
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Ocala Florida 34474
GSK Investigational Site Ocoee Florida 34761
GSK Investigational Site Orlando Florida 32804
GSK Investigational Site West Palm Beach Florida 33401
GSK Investigational Site Lawrenceville Georgia 30046-7650
GSK Investigational Site Niles Illinois 60714
GSK Investigational Site Indianapolis Indiana 46202
GSK Investigational Site Indianapolis Indiana 46227
GSK Investigational Site Terre Haute Indiana 47802
GSK Investigational Site Cedar Rapids Iowa 52403
GSK Investigational Site Kansas City Kansas 66103
GSK Investigational Site Overland Park Kansas 66210
GSK Investigational Site Boston Massachusetts 02115
GSK Investigational Site Minneapolis Minnesota 55404
GSK Investigational Site Robbinsdale Minnesota 55422
GSK Investigational Site Columbia Missouri 65201
GSK Investigational Site Saint Joseph Missouri 64507
GSK Investigational Site Las Vegas Nevada 89109
GSK Investigational Site Las Vegas Nevada 89135
GSK Investigational Site Montclair New Jersey 07042
GSK Investigational Site Morristown New Jersey 07962
GSK Investigational Site New Brunswick New Jersey 08901
GSK Investigational Site Summit New Jersey 07901
GSK Investigational Site Voorhees Township New Jersey 08043
GSK Investigational Site Albany New York 12208
GSK Investigational Site New York New York 10016
GSK Investigational Site Cary North Carolina 27511
GSK Investigational Site Charlotte North Carolina 28203
GSK Investigational Site Durham North Carolina 27710
GSK Investigational Site Hickory North Carolina 28602
GSK Investigational Site Canton Ohio 44710
GSK Investigational Site Kettering Ohio 45409
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Tulsa Oklahoma 74136-1902
GSK Investigational Site Bryn Mawr Pennsylvania 19010
GSK Investigational Site Hershey Pennsylvania 17033
GSK Investigational Site Kingston Pennsylvania 18704
GSK Investigational Site Philadelphia Pennsylvania 19104
GSK Investigational Site Pittsburgh Pennsylvania 15213
GSK Investigational Site West Reading Pennsylvania 19611
GSK Investigational Site Greenville South Carolina 29605
GSK Investigational Site Nashville Tennessee 37203
GSK Investigational Site Arlington Texas 76014
GSK Investigational Site Austin Texas 78731
GSK Investigational Site Beaumont Texas 77702-1449
GSK Investigational Site Bedford Texas 76022
GSK Investigational Site Dallas Texas 75230
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site Dallas Texas 75237
GSK Investigational Site Dallas Texas 75246
GSK Investigational Site Denton Texas 76210
GSK Investigational Site El Paso Texas 79915
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Fredericksburg Texas 78624
GSK Investigational Site Lewisville Texas 75067
GSK Investigational Site Longview Texas 75601
GSK Investigational Site McAllen Texas 78503-1298
GSK Investigational Site Mesquite Texas 75150
GSK Investigational Site Midland Texas 79701
GSK Investigational Site Odessa Texas 79761
GSK Investigational Site Paris Texas 75460
GSK Investigational Site Tyler Texas 75702
GSK Investigational Site Waco Texas 76712
GSK Investigational Site Norfolk Virginia 23502
GSK Investigational Site Richmond Virginia 23230
GSK Investigational Site Salem Virginia 24153
GSK Investigational Site Edmonds Washington 98026
GSK Investigational Site Seattle Washington 98133
GSK Investigational Site Spokane Washington 99202
GSK Investigational Site Vancouver Washington 98684
GSK Investigational Site Yakima Washington 98902
GSK Investigational Site Green Bay Wisconsin 54301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00320385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 25, 2016 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00320385 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →